The document outlines the Modello Generale framework used by the National Academy of Science and IARC to evaluate carcinogenic risks. It involves identifying risk factors, defining dose-response relationships, assessing exposure levels, and characterizing risks. Risk management then evaluates economic, social, health and policy consequences to develop regulatory options.
Critical evaluation of an article titled " Systematic review of basket trials, umbrella trials, and platform trials: A landscape analysis of master protocols"
What is Cohort?
Indication and Elements of Cohort Study.
What is Relative risk and Attributable risk, and its interpretation?
Advantages & disadvantages of Cohort study.
Difference between Case control & Cohort study.
Global Medical Cures™ | NEULASTA- Pediatric PostMarketing Adverse Event ReviewGlobal Medical Cures™
Global Medical Cures™ | NEULASTA- Pediatric PostMarketing Adverse Event Review
DISCLAIMER-
Global Medical Cures™ does not offer any medical advice, diagnosis, treatment or recommendations. Only your healthcare provider/physician can offer you information and recommendations for you to decide about your healthcare choices.
The Transtheoretical Model also called the Stages
of Change model,7 describes how such behavior
change often occurs. The model emphasizes the
need to understand the experience of the person we
are trying to reach in order to help them. To promote
change, interventions must be provided that are
appropriate for the stage in the process that people
are in."
"Meet people where they are:
The guiding principle of “meeting people where
they are” means more than showing compassion
or tolerance to people in crisis. This principle also
asks us to acknowledge that all people we meet are
at different stages of behavior change."
Critical evaluation of an article titled " Systematic review of basket trials, umbrella trials, and platform trials: A landscape analysis of master protocols"
What is Cohort?
Indication and Elements of Cohort Study.
What is Relative risk and Attributable risk, and its interpretation?
Advantages & disadvantages of Cohort study.
Difference between Case control & Cohort study.
Global Medical Cures™ | NEULASTA- Pediatric PostMarketing Adverse Event ReviewGlobal Medical Cures™
Global Medical Cures™ | NEULASTA- Pediatric PostMarketing Adverse Event Review
DISCLAIMER-
Global Medical Cures™ does not offer any medical advice, diagnosis, treatment or recommendations. Only your healthcare provider/physician can offer you information and recommendations for you to decide about your healthcare choices.
The Transtheoretical Model also called the Stages
of Change model,7 describes how such behavior
change often occurs. The model emphasizes the
need to understand the experience of the person we
are trying to reach in order to help them. To promote
change, interventions must be provided that are
appropriate for the stage in the process that people
are in."
"Meet people where they are:
The guiding principle of “meeting people where
they are” means more than showing compassion
or tolerance to people in crisis. This principle also
asks us to acknowledge that all people we meet are
at different stages of behavior change."
Epidemiological studies concept in ophthalmology. This was a presentation done on zoom for the Magrabi ICO Cameroon Eye Institute, Cameroon and Center for Sight Africa, Nigeria. It deals with conceiving a research question, deciding the target population, measures of burden of disease such as prevalence and incidence, measures of associations between exposure and disease- relative risks, confidence intervals, threats to making inferences such as confounders, Bias, and chance, Bradford-Hill guideline, cross sectional study, cohort study, Case-control study, Randomised controlled trials and it concludes with types and use of epidemiological studies.
Epidemiology designs for clinical trials - PubricaPubrica
1. Clinical trial study design
2. Cohort Study design
3. Case-Control Studies
4. Cross-Sectional Studies
5. Ecological Studies
6. Randomized Clinical Trials
Continue Reading: https://bit.ly/3tDt6rH
Reference: https://pubrica.com/services/research-services/experimental-design/
Why Pubrica:
When you order our services, We promise you the following – Plagiarism free | always on Time | 24*7 customer support | Written to international Standard | Unlimited Revisions support | Medical writing Expert | Publication Support | Biostatistical experts | High-quality Subject Matter Experts.
Contact us:
Web: https://pubrica.com/
Blog: https://pubrica.com/academy/
Email: sales@pubrica.com
WhatsApp : +91 9884350006
United Kingdom: +44- 74248 10299
Periodontal disease is a widely prevalent disease worldwide which often gets unnoticed or it often ignored due to its slowly progressive nature. It is of concern since it can cause irrepairable damage to tooth supporting structures if not early diagnosed or treated.
Social and Preventive Medicine Classroom discussion topic on types of Epidemiological study designs available.
sole reference is Park text book 20th edition
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachAyurveda ForAll
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
ABDOMINAL TRAUMA in pediatrics part one.drhasanrajab
Abdominal trauma in pediatrics refers to injuries or damage to the abdominal organs in children. It can occur due to various causes such as falls, motor vehicle accidents, sports-related injuries, and physical abuse. Children are more vulnerable to abdominal trauma due to their unique anatomical and physiological characteristics. Signs and symptoms include abdominal pain, tenderness, distension, vomiting, and signs of shock. Diagnosis involves physical examination, imaging studies, and laboratory tests. Management depends on the severity and may involve conservative treatment or surgical intervention. Prevention is crucial in reducing the incidence of abdominal trauma in children.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
1. MODELLO GENERALE
(National Academy of Science, USA, 1986)
VALUTAZIONE DEL RISCHIO GESTIONE DEL RISCHIO
Identificazione del
fattore di rischio Valutazione delle
(L’agente causa un danno conseguenze economiche,
per la salute?) sociali, politiche e sulla
salute pubblica
Definizione della dose – Caratterizzazione
risposta del rischio
(Qual è la relazione tra (Qual è l’incidenza e
dose e risposta?) l’entità del danno Sviluppo di opzioni
per la salute?) normative
Valutazione della
esposizione
(Quali esposizioni sono Limiti
dimostrate o prevedibili in
diverse condizioni?)
2. http://www.iarc.fr/en/publications/list/
monographs/index.php
IARC Publications
•WHO/IARC Classification of Tumours
•
IARC Working Group Reports
•
IARC Handbooks of Cancer Prevention
•
IARC Monographs on the Evaluation of Carcinogen
•
IARC Scientific Publications Series
3. (a) Exposure data
Data are summarized, as appropriate, on the basis of
elements such as production, use, occurrence and
exposure levels in the workplace and environment
and measurements in human tissues and body fluids.
Quantitative data and time trends are given to
compare exposures in different occupations and
environmental settings. Exposure to biological agents
is described in terms of transmission, prevalence and
persistence of infection.
4. (b) Cancer in humans
Results of epidemiological studies pertinent to an
assessment of human carcinogenicity are
summarized. When relevant, case reports and
correlation studies are also summarized. The target
organ(s) or tissue(s) in which an increase in cancer
was observed is identified. Dose-response and other
quantitative data may be summarized when available
5. (c) Cancer in experimental animals
Data relevant to an evaluation of carcinogenicity in
animals are summarized. For each animal species,
study design and route of administration, it is stated
whether an increased incidence, reduced latency, or
increased severity or multiplicity of neoplasms or
preneoplastic lesions were observed, and the tumour
sites are indicated. If the agent produced tumours
after prenatal exposure or in single-dose
experiments, this is also mentioned. Negative
findings, inverse relationships, dose-response and
other quantitative data are also summarized.
•.
6. (d) Mechanistic and other relevant data
Data relevant to the toxicokinetics (absorption,
distribution, metabolism, elimination) and the
possible mechanism(s) of carcinogenesis (e.g.
genetic toxicity, epigenetic effects) are summarized.
In addition, information on susceptible individuals,
populations and life-stages is summarized. This
section also reports on other toxic effects, including
reproductive and developmental effects, as well as
additional relevant data that are considered to be
important.
7. (d) Mechanistic and other relevant data
Mechanistic and other relevant data may provide evidence of
carcinogenicity and also help in assessing the relevance and
importance of findings of cancer in animals and in humans.
The nature of the mechanistic and other relevant data depends
on the biological activity of the agent being considered. The
Working Group considers representative studies to give a
concise description of the relevant data and issues that they
consider to be important; thus, not every available study is
cited. Relevant topics may include toxicokinetics, mechanisms
of carcinogenesis, susceptible individuals, populations and life-
stages, other relevant data and other adverse effects. When
data on biomarkers are informative about the mechanisms of
carcinogenesis, they are included in this section.
8. B. SCIENTIFIC REVIEW AND EVALUATION
2. Studies of cancer in humans
• (b) Quality of studies considered
It is necessary to take into account the possible roles of bias,
confounding and chance in the interpretation of
epidemiological studies. Bias is the effect of factors in study
design or execution that lead erroneously to a stronger or
weaker association than in fact exists between an agent
and disease. Confounding is a form of bias that occurs
when the relationship with disease is made to appear
stronger or weaker than it truly is as a result of an
association between the apparent causal factor and another
factor that is associated with either an increase or decrease
in the incidence of the disease. The role of chance is
related to biological variability and the influence of sample
size on the precision of estimates of effect.
9. B. SCIENTIFIC REVIEW AND EVALUATION
2. Studies of cancer in humans
• f) Criteria for causality
After the quality of individual epidemiological studies of
cancer has been summarized and assessed, a
judgement is made concerning the strength of
evidence that the agent in question is carcinogenic to
humans. In making its judgement, the Working Group
considers several criteria for causality (Hill, 1965).
A strong association (e.g. a large relative risk) is more
likely to indicate causality than a weak association,
although it is recognized that estimates of effect of small
magnitude do not imply lack of causality and may be
important if the disease or exposure is common.
10. B. SCIENTIFIC REVIEW AND EVALUATION
2. Studies of cancer in humans
• f) Criteria for causality
Associations that are replicated in several studies of the
same design or that use different epidemiological
approaches or under different circumstances of exposure
are more likely to represent a causal relationship than
isolated observations from single studies. If there are
inconsistent results among investigations, possible reasons
are sought (such as differences in exposure), and results of
studies that are judged to be of high quality are given more
weight than those of studies that are judged to be
methodologically less sound.
11. B. SCIENTIFIC REVIEW AND EVALUATION
2. Studies of cancer in humans
• f) Criteria for causality
If the risk increases with the exposure, this is considered
to be a strong indication of causality, although the
absence of a graded response is not necessarily
evidence against a causal relationship. The
demonstration of a decline in risk after cessation of or
reduction in exposure in individuals or in whole
populations also supports a causal interpretation of the
findings.
12. B. SCIENTIFIC REVIEW AND EVALUATION
2. Studies of cancer in humans
• f) Criteria for causality
A number of scenarios may increase confidence in a causal
relationship. On the one hand, an agent may be specific
in causing tumours at one site or of one morphological
type. On the other, carcinogenicity may be evident through
the causation of multiple tumour types.
Temporality, precision of estimates of effect, biological
plausibility and coherence of the overall database are
considered. Data on biomarkers may be employed in an
assessment of the biological plausibility of epidemiological
observations.
13. IARC categories of carcinogenesis,
for humans studies
1. The sufficient category is identical to the causal criteria
defined earlier, i.e., strength of association, dose-response,
consistency, biological plausibility, temporal cogency,
control of confounding and bias, specificity, and
coherence.
14. IARC categories of carcinogenesis,
for humans studies
2. The limited category is used when “a positive
association has been observed between exposure to the
agent, mixture or exposure circumstance and cancer for
which a causal interpretation is considered to be credible,
but change, bias or confounding could not be ruled out
with reasonable confidence”.
15. IARC categories of carcinogenesis,
for humans studies
3. The inadequate category is used when “the available
studies are of insufficient quality, consistency or statistical
power to permit a conclusion regarding the presence or
absence of a causal association, or no data on cancer on
humans are available.
16. IARC categories of carcinogenesis,
for humans studies
4. The lack of evidence category is used when “there are
several adequate studies … which are mutually consistent
in not showing a positive association between exposure to
the agent, mixture or exposure circumstance and any
studied cancer or at any observed level of exposure …
“Lack of carcinogenicity’ is inevitably limited to the
cancer sites, conditions and levels of exposure and length
of observation covered by the available studies. In
addition, the possibility of a very small risk at the levels of
exposure studied can never be excluded”.
17. IARC categories of carcinogenesis,
for animal studies
1. Sufficient evidence exists when “a causal relationship
has been established between the agent or mixture and an
increased incidence of malignant neoplasm … in (a) two
or more species of animals or (b) in two or more
independent studies in one species carried out at different
times or in different laboratories or under different
protocols.”.
18. IARC categories of carcinogenesis,
for animal studies
2. Limited evidence exists when there are “data [that]
suggest a carcinogenic effect but are limited for making a
definitive evaluation because (a) the evidence of
carcinogenicity is restricted to a single experiment; or (b)
there are unresolved questions regarding … dosing,
conduct or interpretation of the study; or (c) the agent or
mixture increases the incidence only of benign neoplasm
… or of certain neoplasm which mat occur spontaneously
in high incidence in certain strains [of animals]”.
19. IARC categories of carcinogenesis,
for animal studies
3. Inadequate evidence exists when there are “studies
[that] cannot be interpreted as showing either the
presence or absence of a carcinogenic effect because of
major qualitative or quantitative limitations, or no data on
cancer in experimental animal are available.”
20. IARC categories of carcinogenesis,
for animal studies
4. Lack of carcinogenicity exists when there are
“adequate studies involving at least two species are
available which show that … the agent or mixture is not
carcinogenic…”
21. IARC Classification Scheme for Human and
Animal Evidence of Carcinogenesis
Animal Evidence
Human Evidence Sufficient Limited Inadequated (-) Carcinogenicity
Sufficient Group 1 Group 1 Group 1 Group 1
Limited Group 2A Group 2B Group 2B Group 2B
Inadequated Group 2B Group 3 Group 3 Group 3
(-) Carcinogenicity Group 2B Group 4 Group 4 Group 4
22. Criteria for Lung Cancer Causation for Silica
Exposure and for Silicosis Between First and
Second IARC Reports
Silica-Exposed Silica-Exposed Workers with Workers with
Point of Evidence Workers, Workers, Silicosis Silicosis
IARC 1986 IARC 1997 IARC 1986 IARC 1997
Strong relative risk ± * *** ***
Dose-response gradient ± ** ± **
Consistent finding * ** *** ***
Controlled confounding ± * ± *
Biological plausibility * ** ± *
Temporal cogency ** ** ** **
Specificity ** ** ** **
Overall coherence * ** *** ***
Note: * = criteria met; ** = more than minimal criteria met; *** = large body of evidence; ± = incomplete evidence.
23. Evidenze e valutazione finale
Animale
Suff Lim Inad
Suff 1 1 1
U
O Lim 2A 2B 2B
M
O (1*)
Inad 2B 3 3
(2A*,3*) (2B*)
24. La Classificazione IARC
degli agenti, delle misture e delle esposizioni (www.iarc.fr)
Gruppo 1 Cancerogeno accertato per l’uomo: vi è sufficiente evidenza di
cancerogenicità nell’uomo in studi epidemiologici adeguati.
Gruppo 2 2A probabile cancerogeno per l’uomo, sulla base di evidenza
limitata nell’uomo ed evidenza sufficiente in animali da
esperimento.
2B possibile cancerogeno per l’uomo, sulla base di evidenza
limitata nell’uomo e evidenzia non del tutto sufficiente negli
animali da esperimento oppure di evidenza sufficiente negli
animali ed evidenza inadeguata nell’uomo.
Gruppo 3 Non classificati per cancerogenicità sull’uomo (tutto ciò che
non rientra nei precedenti viene posto in questo gruppo).
Gruppo 4 Probabilmente non cancerogeno per l’uomo: assenza di
cancerogenicità nell’uomo e negli animali da esperimento; in
presenza di un ampio numero di dati sperimentali